

# EXHIBIT 21

IN THE UNITED STATES DISTRICT COURT  
MIDDLE DISTRICT OF FLORIDA  
ORLANDO DIVISION

IN RE:

SEROQUEL PRODUCTS LIABILITY LITIGATION

CASE NO. 6:06-md-01769-ACC-DAB

MDL DOCKET NO. 1769

-----  
CONFIDENTIAL  
-----

January 10, 2008  
-----

Videotaped Oral Deposition of  
JOHN ANTHONY SCHWARTZ, Ph.D., held in the  
offices of Golkow Technologies, Inc.,  
One Liberty Place, 51st Floor,  
Philadelphia, Pennsylvania beginning at  
approximately 9:08 a.m., before Ann V.  
Kaufmann, a Registered Professional  
Reporter, Certified Realtime Reporter,  
Approved Reporter of the U.S. District  
Court, and a Notary Public.

-----  
  
GOLKOW TECHNOLOGIES, INC.  
One Liberty Place, 51st Floor  
Philadelphia, Pennsylvania 19103  
877.370.3377

Page 290

1 Q. Had you received the data  
2 from study 43 that you had also  
3 promised?  
4 A. I don't recall.  
5 Q. Do you know whether you had  
6 given any of the data from study 41 or  
7 43 to the Japanese marketing company?  
8 A. The answer, I don't know  
9 that. And if we hadn't, that's because  
10 we hadn't thoroughly understood the data  
11 to provide to the HFC. So we need to  
12 ensure that we thoroughly understood  
13 what the data means prior to provision  
14 to the health authorities.  
15 Q. I show you Schwartz  
16 Exhibit No. 25.  
17 A. Uh-huh.  
18 (Below-described document  
19 marked Schwartz Exhibit 25.)  
20 THE WITNESS: Uh-huh.  
21 BY MR. BLIZZARD:  
22 Q. Is this an e-mail that's  
23 dated in December of 2002? I'm sorry --  
24 yes, 2002.

Page 291

1 A. Yes, that's correct.  
2 Q. It's dated December 20,  
3 2002; correct?  
4 A. Correct.  
5 Q. And it's from Joy Russo;  
6 right?  
7 A. Correct.  
8 Q. Do you know who Joy Russo  
9 is?  
10 A. I believe she was a data  
11 manager at the time.  
12 Q. Okay. And she is writing  
13 to Martin Jones, who is a statistician  
14 working on Seroquel studies?  
15 A. Correct.  
16 Q. And this was regarding  
17 glucose for trial 41; correct?  
18 A. Correct.  
19 Q. And does it say "Hi,  
20 Martin" --  
21 A. Yes, it does.  
22 Q. -- "All...values for the  
23 clinically significant glucose are  
24 high"?

Page 292

1 A. Yes.  
2 Q. So it says: "All 7 values  
3 for the clinically significant glucose  
4 are high"?  
5 A. Yes. And this, I recall  
6 now, set off issues because we didn't --  
7 based on the previous safety profile for  
8 Seroquel, we did not expect this. So we  
9 suspected there was something wrong with  
10 the testing.  
11 Q. Or something wrong with the  
12 drug; right?  
13 A. Well, it wasn't indicative  
14 of our previous experience with the  
15 drug.  
16 Q. Okay. So this set off some  
17 alarm bells?  
18 A. Yes.  
19 Q. Okay. And this --  
20 A. In terms that we had to  
21 further investigate the fasting glucose  
22 test.  
23 Q. Okay. Well, while you were  
24 investigating it, did you notify the FDA

Page 293

1 about what Joy Russo told Martin Jones?  
2 A. Referring --  
3 MR. SCHOON: Objection,  
4 form.  
5 A. -- to Exhibit 25?  
6 Q. Yes.  
7 A. Not that I'm aware.  
8 Q. Did you tell doctors who  
9 were prescribing Seroquel or patients  
10 who were taking Seroquel this  
11 information?  
12 A. Again, this was preliminary  
13 results. It wasn't consistent with our  
14 previous experience with Seroquel and we  
15 suspected that there was an issue with  
16 the fasting glucose test.  
17 Q. Okay. Well, just to be on  
18 the safe side, did you think it would be  
19 prudent to let people know that there  
20 was this result out there and that you  
21 would need to study it further?  
22 MR. SCHOON: Objection,  
23 form.  
24 A. We wanted to make sure we

Page 294

1 thoroughly understood the situation  
2 before notifying people.  
3 Q. Okay. Why wouldn't you  
4 want to notify them?  
5 A. Pardon?  
6 Q. Why wouldn't you want to  
7 notify them that there was this issue  
8 and that there would be further study  
9 done?  
10 A. We wanted to ensure that we  
11 clearly understood the issue. And what  
12 we did find is the fasting glucose test,  
13 actually the subjects weren't fasted, so  
14 they were inconclusive results or  
15 actually erroneous results, when you  
16 assume a test is being -- the subject is  
17 fasting when indeed they aren't.  
18 Q. All of the data here was  
19 not on fasting blood glucose, was it?  
20 A. I believe it was.  
21 Q. Well, you used different  
22 values. You didn't use the fasting  
23 blood glucose value to judge whether  
24 somebody's glucose was high; correct?

Page 295

1 A. I don't know what values  
2 were used. That wasn't part of my work.  
3 Q. Do you remember the value  
4 200 milliliters per deciliter?  
5 A. No, I don't.  
6 Q. Okay. Did you approve of  
7 this information not being given to FDA?  
8 MR. SCHOON: Objection,  
9 form.  
10 A. I don't think we ever  
11 discussed giving the information to the  
12 FDA that I recall.  
13 Q. Okay.  
14 A. And because we wanted to  
15 ensure we clearly understood the  
16 situation.  
17 Q. Okay. Did the global  
18 product team know about this  
19 information?  
20 A. Yes.  
21 Q. Did the senior executive  
22 team know about this information?  
23 A. That I don't know.  
24 Q. Who would have been

Page 296

1 responsible for notifying the senior  
2 executive team?  
3 A. I assume it might have been  
4 Alex Oldham. But, again, we wouldn't  
5 have notified them until we fully  
6 understood the situation.  
7 Q. Okay. Now, how did you  
8 propose to more fully understand the  
9 information?  
10 A. As I understood it, the  
11 team went back and looked at the timings  
12 when the fasting glucose blood samples  
13 were taken. And as I recall, the  
14 timings indicated that the samples or  
15 the subject would not have been fasted.  
16 Q. Is that the only way you  
17 looked at this issue?  
18 A. That's the only one I'm  
19 aware of.  
20 Q. Okay. Do you know about  
21 study 125?  
22 A. Yes.  
23 Q. Okay. What is study 125?  
24 A. 125 is a metabolism study

Page 297

1 to better understand the metabolic  
2 profile of Seroquel and other atypicals.  
3 Q. Okay. And does it look at  
4 glucose levels?  
5 A. Yes.  
6 Q. So is it a study that  
7 resulted or came out of the results of  
8 study 41?  
9 A. Yes. As I understand it,  
10 is that we felt we needed a better  
11 controlled situation to fully  
12 characterize the metabolic profile of  
13 Seroquel because we could not get  
14 properly fasted blood samples.  
15 (Below-described document  
16 marked Schwartz Exhibit 26.)  
17 BY MR. BLIZZARD:  
18 Q. I'm going to hand you what  
19 I've marked as Schwartz Exhibit No. 26.  
20 A. Uh-huh.  
21 Q. Let's look first on the  
22 last page, which is the first e-mail in  
23 this chain.  
24 A. Okay.